Johns Hopkins HIV Guide
Letermovir
Letermovir is a topic covered in the Johns Hopkins HIV Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Prophlyaxis of cytomegalovirus infection (CMV) in patients (> 18 years of age) who are CMV-seropositive and have undergone an allogeneic stem cell transplant
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Prophlyaxis of cytomegalovirus infection (CMV) in patients (> 18 years of age) who are CMV-seropositive and have undergone an allogeneic stem cell transplant
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 6, 2018
Citation
Dzintars, Kathryn. "Letermovir." Johns Hopkins HIV Guide, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir.
Dzintars K. Letermovir. Johns Hopkins HIV Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir. Accessed April 1, 2023.
Dzintars, K. (2018). Letermovir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir
Dzintars K. Letermovir [Internet]. In: Johns Hopkins HIV Guide. ; 2018. [cited 2023 April 01]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Letermovir
ID - 545271
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/06/06/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
